Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease

Antiviral Therapy

Volumn 18, Issue 3, 2013, Pages 399-408

  Schackman, Bruce R ^a   Haas, David W ^b   Becker, Jessica E ^c   Berkowitz, Bethany K ^c   Sax, Paul E ^d,e   Daar, Eric S ^f   Ribaudo, Heather J ^g   Freedberg, Kenneth A ^c,d,h  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARBOR UCLA MEDICAL CENTER   (United States)

^g CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; EMTRICITABINE; GLUCURONOSYLTRANSFERASE 1A1; RITONAVIR; TENOFOVIR;

AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE; GENETIC SCREENING; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; UGT1A1 GENE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; FEMALE; GENETIC TESTING; GENOTYPE; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 84878098923     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2500     Document Type: Article

References (41)

1. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347:578-581. (Pubitemid 26070740)
2. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:1171-1175.
3. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33:1729-1739. (Pubitemid 41539973)
4. Lubomirov R, Colombo S, di Iulio J, et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis 2011; 203:246-257.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 27 March 2012. Accessed 6 August 2012.) Available from http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentGL.pdf
6. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008; 22:2025-2033.
7. Haas DW, Kuritzkes DR, Ritchie MD, et al. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials 2011; 12:277-285.
8. Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009; 115:3858-3867.
9. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-831. (Pubitemid 32222162)
10. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44:990-997. (Pubitemid 44674030)
11. Morris BL, Scott CA, Wilkin TJ, et al . Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin Trials 2012; 13: 1-10.
12. Gold MR, Seigel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press 1996.
13. Braithwaite RS, Goulet J, Kudel I, Tsevat J, Justice AC. Quantifying the decrement in utility from perceived side effects of combination antiretroviral therapies in patients with HIV. Value Health 2008; 11:975-979.
14. Schackman BR, Scott CA, Sax PE, et al. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis 2007; 45:1062-1070. (Pubitemid 47580359)
15. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954.
16. Freedberg KA, Scharfstein JA, Seage GR, III, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279:130-136.
17. Multicenter AIDS Cohort Study (MACS) Public Dataset. Release P04. Springfield: National Technical Information Service 1995.
18. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
19. United Nations, Department of Economic and Social Affairs, Population Division. World population prospects: the 2008 revision, highlights. Working paper number. ESA/P/WP.210. 2009.
20. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-540. (Pubitemid 44885619)
21. Daar ES, Tierney C, Fischl MA, et al . Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445-456.
22. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40:404-412. (Pubitemid 41669173)
23. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685-694. (Pubitemid 40593073)
24. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet 2007; 369:1261-1269. (Pubitemid 46553846)
25. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
26. Shenouda N. Red Book. Montvale, NJ: Thomson PDR 2009.
27. Department of Health and Human Services. Office of Inspector General. Medicaid drug price comparisons: average manufacturer price to published prices. (Updated 1 June 2005. Accessed 29 August 2012.) Available from http://oig.hhs.gov/oei/reports/oei-05-05-00240.pdf
28. Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009; 49:1570-1578.
29. Centers for Medicare and Medicaid Services. Medicare physician fee schedule. (Updated 27 March 2012. Accessed 6 August 2012.) Available from https://www.cms.gov/apps/physician-fee-schedule/
30. Gebo KA, Moore RD, Fleishman JA. The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV. Hopkins HIV Rep 2003; 15:5-6.
31. Centers for Medicare and Medicaid Services. Clinical laboratory fee schedule. (Updated 23 March 2012. Accessed 6 August 2012.) Available from http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ ClinicalLabFeeSched/clinlab.html
32. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 1999; 9: 591-599.
33. Hunink MGM, Glasziou PP, Siegel JE, et al. Decision making in health and medicine: integrating evidence and values. Cambridge: Cambridge University Press 2001.
34. Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics 2010; 28: 1025-1039.
35. Christopoulos KA, Das M, Colfax GN. Linkage and retention in HIV care among men who have sex with men in the United States. Clin Infect Dis 2011; 52 Suppl 2:S214-S222.
36. Horstmann E, Brown J, Islam F, Buck J, Agins BD. Retaining HIV-infected patients in care: where are we? Where do we go from here? Clin Infect Dis 2010; 50:752-761.
37. Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment - United States. MMWR Morb Mortal Wkly Rep 2011; 60:1618-1623.
38. Wilke RA, Xu H, Denny JC, et al. The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther 2011; 89:379-386.
39. Ribaudo HJ, Daar ES, Tierney C, et al. Premature discontinuation of atazanavir/ritonavir and UGT1A1 variants: ACTG Protocol A5202. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012, Seattle, WA, USA. Abstract 597.
40. AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb, Gilead Sciences, Merck, Tibotec Therapeutics. Comparative study of three NNRTI-sparing HAART regimens. (Updated 6 October 2011. Accessed 22 May 2012.) Available from http://clinicaltrials.gov/ ct2/show/NCT00811954?term=NCT00811954&rank=1
41. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002; 22:27-38. (Pubitemid 34087688)